May Hill Capital’s Relay Therapeutics RLAY Stock Holding History

May Hill Capital’s Portfolio RLAY Stock Details RLAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-10,914	Closed	-$37.8K	–	209
2025 Q2	$37.8K	Buy	+10,914	New	+$32.5K	0.01%	197

Other funds holding RLAY

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

May Hill Capital's RLAY Position: Q3 2025 in Review

May Hill Capital sold out of Relay Therapeutics (RLAY) in Q3 2025, closing a stake of 10,914 shares — an estimated $37.8K sold.

May Hill Capital first reported a position in RLAY in Q2 2025 and held it in 1 quarter. The position peaked at $37.8K in Q2 2025. 199 funds tracked by Wall St. Rank hold RLAY as of Q3 2025.

May Hill Capital reported no remaining Relay Therapeutics position as of Q3 2025 after selling out during the quarter.
May Hill Capital sold 10,914 Relay Therapeutics shares in Q3 2025, an estimated $37.8K.
May Hill Capital first reported a position in Relay Therapeutics in Q2 2025 and held it in 1 quarter.
May Hill Capital's Relay Therapeutics position peaked at $37.8K in Q2 2025.
199 funds tracked by Wall St. Rank held Relay Therapeutics as of Q3 2025.

Based on May Hill Capital's 13F filing for Q3 2025, filed 7 Nov 2025.